Emerging opportunistic yeast infections – literature review

Authors

  • Gordana Mirchevska Institute of microbiology and parasitology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia

DOI:

https://doi.org/10.3889/aph.2025.6546

Keywords:

invasive fungal infections, yeasts, multi drug resistant, antifungals

Abstract

The growing threat of fungal infections demands immediate attention from healthcare systems in all countries. With the advancement of modern medicine and a growing population of immunosuppressed and immunocompromised patients, as well as critically ill patients, increasingly frequent diagnoses of invasive yeast infections have become an important cause of morbidity and mortality. In the last decade, increased incidence of non-albicans Candida species infection compared to C. albicans has been registered worldwide. Several non-albicans Candida species, such as C. glabrata and C. krusei, may be resistant to azole antifungal therapy The emergence of multidrug-resistant C. auris is the latest threat in many countries, since this fungus can cause intrahospital infections. Trichosporon species are the second most common cause of invasive yeast infections in patients with haematological malignancies, and can be resistant to amphotericin and echinocandins. Despite diagnostic and therapeutic advances, cryptococcosis continues to be a disease with unacceptably high incidence and mortality, particularly in resource-limited settings. Rhodotorula species can be a significant cause of catheter-related fungaemia, sepsis, and invasive disease in severely immunosuppressed patients. Other uncommon yeasts that can cause invasive disease in severely immunosuppressed patients include Magnusiomyces capitatus, Geotrichum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae, Malassezia furfur and Sporobolomyces species. Although rare yeasts are emerging as opportunistic human pathogens, diagnosis remains challenging and treatment suboptimal. Therefore, enhanced awareness of fungal infections is crucial among healthcare providers, and this requires great knowledge and understanding, and appropriate diagnostic testing, so every segment of the healthcare system can contribute to address the challenges posed by fungal infections.

Downloads

Download data is not yet available.

References

Bahram M, Netherway T. Fungi as mediators linking organisms and ecosystems. FEMS Microbiol Rev 2022;46:fuab058. DOI: 10.1093/femsre/fuab058

Wickes BL, Wiederhold NP. Molecular diagnostics in medical mycology. Nat Commun 2018;9:5135. DOI: 10.1038/s41467-018-07553-8

Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 2018; 360:739-742. DOI: 10.1126/science.aap7999

Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017;3:57. DOI: 10.3390/jof3040057 PMID: 29371573 PMCID: PMC5753159

Hlaing KM, Monday LM, Nucci M, Nouér SA, Revankar SG. Invasive fungal infections associated with COVID-19. J Fungi (Basel) 2023;9:667. DOI: 10.3390/jof9060667 PMID: 37367582 PMCID: PMC10301787

Ulloque-Badaracco JR, Copaja-Corzo C, Hernandez-Bustamante EA, Cabrera-Guzmán JC, Huayta-Cortez MA, Carballo-Tello XL, et al. Fungal infections in patients after recovering from COVID-19: a systematic review. Ther Adv Infect Dis 2024;11:20499361241242963. DOI: 10.1177/20499361241242963 PMID: 38628602 PMCID: PMC11018917

Parums DV. Editorial: The World Health Organization (WHO) Fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic. Med Sci Monit 2022;28:e939088. DOI: 10.12659/MSM.939088 PMID: 36453151 PMCID: PMC9718879

Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, et al. Candida albicans-the virulence factors and clinical manifestations of infection. J Fungi (Basel) 2021;7:79. DOI: 10.3390/jof7020079 PMID: 33578720 PMCID: PMC7917421

Nobile CJ, Johnson AD. Candida albicans biofilms and human disease. Annu Rev Microbiol 2015;69:71-92. DOI: 10.1146/annurev-micro-091014-104330 PMID: 26488273 PMCID: PMC4930275

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers 2018;4:18026. DOI: 10.1038/nrdp.2018.26 PMID: 29749387

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Open Forum Infect Dis 2019;6:S79-S94. DOI: 10.1093/ofid/ofy358 PMID: 30895218 PMCID: PMC6419935

Tsay SV, Mu Y, Williams S, Epson E, Nadle J, Bamberg WM, et al. Burden of Candidemia in the United States, 2017. Clin Infect Dis 2020;71:e449-e453. DOI: 10.1093/cid/ciaa193 PMID: 32052053 PMCID: PMC7454394

Meneghello S, Bernabè G, Di Pietra G, Di Sopra S, Del Vecchio C, Cattelan AM, et al. Prevalence, species distribution and resistance of candidemia in pediatric and adult patients in a Northeast Italy University Hospital. J Fungi (Basel) 2024;10:707. DOI: 10.3390/jof10100707 PMID: 38921363 PMCID: PMC11207590

Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22. DOI: 10.1007/s10096-004-1109-5 PMID: 15057529

Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). Clin Microbiol Infect 2015;21:87.e1-87.e10. DOI: 10.1016/j.cmi.2014.08.011 PMID: 25270048

Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis 2023;23:751-761. DOI: 10.1016/S1473-3099(22)00872-6 PMID: 36738747

Wolfgruber S, Sedik S, Klingspor L, Tortorano A, Gow NAR, Lagrou K, et al. Insights from Three Pan-European Multicentre Studies on invasive Candida infections and outlook to ECMM Candida IV. Mycopathologia. 2024;189(4):70. doi: 10.1007/s11046-024-00871-0.

Montagna MT, Lovero G, Borghi E, Amato G, Andreoni S, Campion L, et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014;18:661-74. PMID: 24706310

Parambath S, et al. Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List. Med Mycol 2024;62:myae045. DOI: 10.1093/mmy/myae045 PMID: 38813851.

Arsić Arsenijević V, Otašević S, Janić D, Minić P, Matijašević J, Medić D, et al. Candida bloodstream infections in Serbia: First multicentre report of a national prospective observational survey in intensive care units. Mycoses. 2018;61(2):70-78. doi: 10.1111/myc.12700. Epub 2017 Sep 28. PMID: 28872706.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009;53:41-44. DOI: 10.1111/j.1348-0421.2008.00083.x PMID: 19161556

Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2017;13:e1006290. DOI: 10.1371/journal.ppat.1006290 PMID: 28542486 PMCID: PMC5436850

Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog 2020;16:e1008921. DOI: 10.1371/journal.ppat.1008921 PMID: 33091071 PMCID: PMC7580931

Caceres DH, Mohd Tap R, Alastruey-Izquierdo A, Hagen F. Detection and control of fungal outbreaks. Mycopathologia 2020;185:741-745. DOI: 10.1007/s11046-020-00479-0 PMID: 32737792 PMCID: PMC7393625

Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care 2018;6:69. DOI: 10.1186/s40560-018-0342-4 PMID: 30410743 PMCID: PMC6206787

de Cássia Orlandi Sardi J, Silva DR, Soares Mendes-Giannini MJ, Rosalen PL. Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options. Microb Pathog 2018;125:116-121. DOI: 10.1016/j.micpath.2018.09.014 PMID: 30223078

Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist 2017;10:155-165. DOI: 10.2147/IDR.S116229 PMID: 28652784 PMCID: PMC5478407

Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al. Candida auris: a review of the literature. Clin Microbiol Rev 2017;31:e00029-17. DOI: 10.1128/CMR.00029-17 PMID: 29142078 PMCID: PMC5740971

Mattingly AS, Rose L, Eddington HS, Trickey AW, Cullen MR, Morris AM, et al. Trends in US Surgical Procedures and Health Care System Response to Policies Curtailing Elective Surgical Operations During the COVID-19 Pandemic. JAMA Netw Open 2021;4:e2138038. DOI: 10.1001/jamanetworkopen.2021.38038 PMID: 34878550 PMCID: PMC8654261

Suleyman G, Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 2021;35:1027-1053. DOI: 10.1016/j.idc.2021.07.003 PMID: 34752221

Abalkhail A, Alslamah T. Institutional factors associated with infection prevention and control practices globally during the infectious pandemics in resource-limited settings. Vaccines (Basel) 2022;10:1811. DOI: 10.3390/vaccines10111811 PMID: 36366344 PMCID: PMC9696233

Dao A, Kim HY, Garnham K, Kidd S, Sati H, Perfect J, et al. Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List. Med Mycol 2024;62:myae043. DOI: 10.1093/mmy/myae043 PMID: 38813850

Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc 2013;124:61-79. PMID: 23874010 PMCID: PMC3715907

May R, Stone N, Wiesner D, et al. Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol 2016;14:106-117. DOI: 10.1038/nrmicro.2015.6 PMID: 26772911 PMCID: PMC4978612

Zhu LP, Wu JQ, Xu B, et al. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med Mycol 2010;48:570-9. DOI: 10.3109/13693780903437876 PMID: 20055735

Li X, Paccoud O, Chan KH, Yuen KY, Manchon R, Lanternier F, et al. Cryptococcosis associated with biologic therapy: A Narrative Review. Open Forum Infect Dis 2024;11:ofae316. DOI: 10.1093/ofid/ofae316 PMID: 38868304 PMCID: PMC11167057

Gangadharan SS, Raveendranath S. Cryptococcosis in oncology patients: a case series in a tertiary care cancer centre. Iran J Microbiol 2023;15:821-825. DOI: 10.18502/ijm.v15i6.14159 PMID: 38156302 PMCID: PMC10752525

Spadari CdC, Wirth F, Lopes LB, Ishida K. New approaches for cryptococcosis treatment. Microorganisms 2020;8:613. DOI: 10.3390/microorganisms8040613 PMID: 32429590 PMCID: PMC7232474

Li H, Guo M, Wang C, Li Y, Fernandez AM, Ferraro TN, et al. Epidemiological study of Trichosporon asahii infections over the past 23 years. Epidemiol Infect 2020;148:e169. DOI: 10.1017/S0950268820001624 PMID: 32703332 PMCID: PMC7439294

Nguyen JK, Schlichte MJ, Schady D, Pourciau CY. Fatal disseminated Trichosporon asahii fungemia in a child with acute lymphoblastic leukemia and a morbilliform eruption. Pediatr Dermatol 2018;35:e86-e87. DOI: 10.1111/pde.13471 PMID: 29457264

Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev 2011;24:682-700. DOI: 10.1128/CMR.00003-11 PMID: 21976604 PMCID: PMC3194828

Guého E, Improvisi L, de Hoog GS, Dupont B. Trichosporon on humans: a practical account. Mycoses 1994;37:3-10. DOI: 10.1111/j.1439-0507.1994.tb00277.x PMID: 7935588

Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 2009;49:0-7. DOI: 10.1086/599614 PMID: 19489715

De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821. DOI: 10.1086/588660 PMID: 18462102

de Almeida Júnior JN, Hennequin C. Invasive Trichosporon infection: a systematic review on a re-emerging fungal pathogen. Front Microbiol 2016;7:1629. DOI: 10.3389/fmicb.2016.01629 PMID: 27803695 PMCID: PMC5067569

Kourti M, Roilides E. Invasive trichosporonosis in neonates and pediatric patients with malignancies or hematologic disorders. Pathogens 2022;11:242. DOI: 10.3390/pathogens11020242 PMID: 35215202 PMCID: PMC8878408

Castano G, Yarrarapu SNS, Mada PK. Trichosporonosis. StatPearls 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482477/ PMID: 29493986

Go SE, Lee KJ, Kim Y, Choi JK, Kim YJ, Lee DG. Catheter-related trichosporon asahii bloodstream infection in a neutropenic patient with myelodysplastic syndrome. Infect Chemother 2018;50:138-143. DOI: 10.3947/ic.2018.50.2.138 PMID: 29968983 PMCID: PMC6026363

Dolan AM, Hoban T, Brennan G, Flanagan PR, O'Rourke S, Teoh TK, et al. Magnusiomyces capitatus, an Unusual Cause of Invasive Fungal Infections in Neutropenic Patients: Case Reports and Outbreak Investigation. Mycopathologia 2025;190:8. DOI: 10.1007/s11046-024-00871-0

Ortiz-Álvarez J, Reséndiz-Sánchez J, Juárez-Montiel M, Hernández-García JA, Vázquez-Guerrero E, Hernández-Rodríguez C, et al. Invasive fungal infection caused by Magnusiomyces capitatus in an immunocompromised pediatric patient with acute lymphoblastic leukemia in Mexico City: A case report. J Fungi (Basel) 2022;8:851. DOI: 10.3390/jof8080851 PMID: 36012842 PMCID: PMC9409336

Bouza E, Muñoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004;10(Suppl 1):76-85. DOI: 10.1111/j.1470-9465.2004.00862.x PMID: 14748806

Martino R, Salavert M, Parody R, Tomás JF, De La Cámara R, Vázquez L, et al. Blastoschizomyces capitatus infection in patients with leukemia: Report of 26 cases. Clin Infect Dis 2004;38:335-341. DOI: 10.1086/380643 PMID: 14727210

Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: A retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005;43:1818-1828. DOI: 10.1128/JCM.43.4.1818-1828.2005 PMID: 15814998 PMCID: PMC1081355

Buchta V, Bolehovská R, Hovorková E, Cornely OA, Seidel D, Žák P. Saprochaete clavata invasive infections- A new threat to hematological-oncological patients. Front Microbiol 2019;10:2196. DOI: 10.3389/fmicb.2019.02196 PMID: 31608031 PMCID: PMC6769163

D'Assumpcao C, Lee B, Heidari A. A Case of Magnusiomyces capitatus peritonitis without underlying malignancies. J Investig Med High Impact Case Rep 2018;6:2324709618795268. DOI: 10.1177/2324709618795268 PMID: 30186588 PMCID: PMC6123035

Meena S, Singh G, Dabas Y, Rajshekhar P, Xess I. Geotrichum candidum in infective endocarditis. J Glob Infect Dis 2017;9:127-128. DOI: 10.4103/jgid.jgid_29_17 PMID: 28855777 PMCID: PMC5563030

Duran Graeff L, Seidel D, Vehreschild MJ, Hamprecht A, Kindo A, Racil Z, et al. Invasive infections due to Saprochaete and Geotrichum species: report of 23 cases from the FungiScope Registry. Mycoses 2017;60:273-279. DOI: 10.1111/myc.12595 PMID: 28066941

Mawad TN, Alfaifi RA, Almazyed OM, Alhumaidi RA, Alsubaie AM. Fungemia due to Saprochaete capitata in a non-neutropenic critically ill patient. Cureus 2023;15:e51147. DOI: 10.7759/cureus.51147 PMID: 38196941 PMCID: PMC10776090

Pottier I, Gente S, Vernoux JP, Guéguen M. Safety assessment of dairy microorganisms: Geotrichum candidum. Int J Food Microbiol 2008;126:327-32. DOI: 10.1016/j.ijfoodmicro.2008.05.013 PMID: 18579247

Kurtzman C, Fell JW. The Yeasts - A Taxonomic Study. 4th Edition. Elsevier; 1998. ISBN: 9780080542690

Wirth F, Goldani LZ. Epidemiology of Rhodotorula: an emerging pathogen. Interdiscip Perspect Infect Dis 2012;2012:465717. DOI: 10.1155/2012/465717 PMID: 22536240 PMCID: PMC3321564

García-Suárez J, Gómez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses 2011;54:318-24. DOI: 10.1111/j.1439-0507.2009.01807.x PMID: 19925568

Spiliopoulou A, Anastassiou ED, Christofidou M. Rhodotorula fungemia of an intensive care unit patient and review of published cases. Mycopathologia 2012;174:301-309. DOI: 10.1007/s11046-012-9553-8 PMID: 22623107

Jarros IC, Veiga FF, Corrêa JL, Barros ILE, Gadelha MC, Voidaleski MF, et al. Microbiological and virulence aspects of Rhodotorula mucilaginosa. EXCLI J 2020;19:687-704. DOI: 10.17179/excli2020-1198 PMID: 32665771 PMCID: PMC7349877

Zhou M, Li Y, Kudinha T, Xu Y, Liu Z. Kodamaea ohmeri as an Emerging Human Pathogen: A Review and Update. Front Microbiol 2021;12:736582. DOI: 10.3389/fmicb.2021.736582 PMID: 34566932 PMCID: PMC8456036

Santino I, Bono S, Borruso L, Bove M, Cialdi E, Martinelli D, et al. Kodamaea ohmeri isolate from two immunocompromised patients: first report in Italy. Mycoses 2013;56:179-81. DOI: 10.1111/j.1439-0507.2012.02232.x PMID: 22882303

Shaaban H, Choo HF, Boghossian J, Perez G. Kodamaea ohmeri fungemia in an immunocompetent patient treated with micafungin: case report and review of the literature. Mycopathologia 2010;170:223-8. DOI: 10.1007/s11046-010-9316-3 PMID: 20490634

Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2014;20(Suppl 3):76-98. DOI: 10.1111/1469-0691.12360 PMID: 24476100

Rhimi W, Theelen B, Boekhout T, Otranto D, Cafarchia C. Malassezia spp. Yeasts of emerging concern in fungemia. Front Cell Infect Microbiol 2020;10:370. DOI: 10.3389/fcimb.2020.00370 PMID: 32850475 PMCID: PMC7396662

Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer JA, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 2013;498:367-70. DOI: 10.1038/nature12171 PMID: 23698366 PMCID: PMC3718715

Vijaya Chandra SH, Srinivas R, Dawson TL Jr, Common JE. Cutaneous Malassezia: commensal, pathogen, or protector? Front Cell Infect Microbiol 2021;10:614446. DOI: 10.3389/fcimb.2020.614446 PMID: 33585270 PMCID: PMC7873985

Baker RM, Stegink RJ, Manaloor JJ, Schmitt BH, Stevens JC, Christenson JC. Malassezia pneumonia: A rare complication of parenteral nutrition therapy. JPEN J Parenter Enteral Nutr 2016;40:1194-1196. DOI: 10.1177/0148607115588337 PMID: 26002912

Rosales CM, Jackson MA, Zwick D. Malassezia furfur meningitis associated with total parenteral nutrition subdural effusion. Pediatr Dev Pathol 2004;7:86-90. DOI: 10.1007/s10024-003-0101-x PMID: 15255036

Tragiannidis A, Bisping G, Koehler G, Groll AH. Minireview: Malassezia infections in immunocompromised patients. Mycoses 2010;53:187-95. DOI: 10.1111/j.1439-0507.2009.01814.x PMID: 19925569

Eschete ML, West BC. Saccharomyces cerevisiae septicemia. Arch Intern Med 1980;140:1539. PMID: 7425782

Fadhel M, Patel S, Liu E, Levitt M, Asif A. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med Mycol Case Rep 2018;23:23-25. DOI: 10.1016/j.mmcr.2018.11.003 PMID: 30505890 PMCID: PMC6251329

Stefanatou E, Kompoti M, Paridou A, Koutsodimitropoulos I, Giannopoulou P, Markou N, et al. Probiotic sepsis due to Saccharomyces fungaemia in a critically ill burn patient. Mycoses 2011;54:e643-6. DOI: 10.1111/j.1439-0507.2011.02020.x PMID: 21615541

Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559-68. DOI: 10.1086/497632 PMID: 16267727

Hamoud S, Keidar Z, Hayek T. Recurrent Saccharomyces cerevisiae fungemia in an otherwise healthy patient. Isr Med Assoc J 2011;13:575-6. PMID: 21991721

Cobban A, Edgcomb VP, Burgaud G, Repeta D, Leadbetter ER. Revisiting the pink-red pigmented basidiomycete mirror yeast of the phyllosphere. Microbiologyopen 2016;5:846-855. DOI: 10.1002/mbo3.377 PMID: 27465122 PMCID: PMC5111565

Morris JT, Beckius M, McAllister CK. Sporobolomyces infection in an AIDS patient. J Infect Dis 1991;164:623-4. DOI: 10.1093/infdis/164.3.623 PMID: 1869844

McNicholas S, McDermott H, Power L, Johnson EM, Moroney J, Humphreys H, et al. Sporobolomyces roseus in the cerebrospinal fluid of an immunocompetent patient--to treat or not to treat? J Med Microbiol 2012;61:295-296. DOI: 10.1099/jmm.0.036715-0 PMID: 22034161

Rantala A, Niinikoski J, Lehtonen OP. Yeasts in blood cultures: impact of early therapy. Scand J Infect Dis 1989;21:557-61. DOI: 10.3109/00365548909037885 PMID: 2587957

Sharma V, Shankar J, Kotamarthi V. Endogeneous endophthalmitis caused by Sporobolomyces salmonicolor. Eye 2006;20:945-946. DOI: 10.1038/sj.eye.6702076 PMID: 16167077

Published

2025-12-30

How to Cite

1.
Mirchevska G. Emerging opportunistic yeast infections – literature review. Arch Pub Health [Internet]. 2025 Dec. 30 [cited 2026 Nov. 21];17(2). Available from: https://journals.mk/index.php/aph/article/view/6546

Most read articles by the same author(s)